ETV7 and breast cancer: These in vivo results are consistent with the in vitro results, further suggesting that exosomal miR-361-3p can activate the PAI-1/ERK pathway by targeting ETV7 and BATF2, thereby enhancing cell viability and ultimately leading to malignant progression of BC (Fig. 5G).